U.S. Markets closed

Supernus Pharmaceuticals Garners 89% ‘Buy’ Ratings in September

Daniel Collins
Supernus Pharmaceuticals Garners 89% ‘Buy’ Ratings in September

On September 11, Supernus Pharmaceuticals (SUPN) stock closed at $48.80, up 1.99% from its closing price of $47.85 on September 10. The company’s September 11 stock price was 26.0% below its 52-week high of $61.25 on June 29. Supernus Pharmaceuticals hit its 52-week low of $33.30 on November 7, 2017.